Phase I trial of SCIB-1 companion diagnostic [ImmunTraCkeR] to investigate the immune-modulatory effect of SCIB-1 vaccine [ImmunoBody] in patients with stage III/IV metastatic melanoma

Trial Profile

Phase I trial of SCIB-1 companion diagnostic [ImmunTraCkeR] to investigate the immune-modulatory effect of SCIB-1 vaccine [ImmunoBody] in patients with stage III/IV metastatic melanoma

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2015

At a glance

  • Drugs SCIB 1 (Primary)
  • Indications Malignant melanoma
  • Focus Diagnostic use
  • Most Recent Events

    • 10 Aug 2015 New trial record
    • 30 Jul 2015 Scancell and ImmunID have entered into an agreement to collaborate on a study of SCIB-1 companion diagnostic [ImmunTraCkeR] to investigate the immune-modulatory effect of SCIB-1 vaccine [ImmunoBody] in patients with stage III/IV metastatic melanoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top